We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
SLENYTO (RAD Data Australia Pty Ltd)
Product name
SLENYTO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 working days (175)
Active ingredients
melatonin
Registration type
EOI
Indication
SLENYTO (modified release tablet) is now indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.